A deal that gives OSL 20-30 million in cash will
1. Allow funding to start a pivotal RCT in USA for FDA approval in pancreatic ca.
2. Buy time until German GBA funding.
3. Complete TRIPP study that allows expansion of label to Folfirinox use and
4. Complete percutaneous study
The German funding would cover a lot of the company's running costs for a couple of years.
The other option is give up US rights in return for cash and royalties.
Pancreatic Cancer in the Media, page-60
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $30.27M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.9¢ | 0.7¢ | $209.6K | 26.25M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 41 | 21920406 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 6056633 | 6 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| OSL (ASX) Chart |